- Home
- VRTX
as 06-27-2025 12:34pm EST
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 115.6B | IPO Year: | 1991 |
| Target Price: | $510.48 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 26 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $377.85 - $519.88 | Next Earning Date: | 07-31-2025 |
| Revenue: | $11,099,700,000 | Revenue Growth: | 8.98% |
| Revenue Growth (this year): | 10.48% | Revenue Growth (next year): | 10.69% |
Stock Insider Trading Activity of Vertex Pharmaceuticals Incorporated (VRTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | May 15 '25 | Sell | $424.69 | 52 | $22,083.88 | 23,281 | |
| Bhatia Sangeeta N. | VRTX | Director | May 1 '25 | Sell | $505.86 | 400 | $202,344.00 | 4,831 |
Latest Vertex Pharmaceuticals Incorporated News
VRTX Breaking Stock News: Dive into VRTX Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug
StockStory
4 days ago
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call
Zacks
5 days ago
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
Insider Monkey
6 days ago
Vertex Pharmaceuticals Presents “Unprecedented” Data for T1D Cell Therapy Zimislecel, Shows Durable Benefit
Clinical Trials Arena
7 days ago
Vertex presents data from Phase I/II stage of trial for type 1 diabetes
MT Newswires
7 days ago
Vertex Pharmaceuticals, Ono Sign License Deal for Povetacicept in Japan, South Korea
Business Wire
8 days ago
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
Business Wire
10 days ago
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
Compare VRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRTX Vertex Pharmaceuticals Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.